Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
03 mai 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human...
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
26 avr. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
20 avr. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA...
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
29 mars 2023 08h00 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
22 mars 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended...
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
02 mars 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
09 févr. 2023 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
19 déc. 2022 07h37 HE
|
Wave Life Sciences USA, Inc.
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation...
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
13 déc. 2022 07h30 HE
|
Wave Life Sciences USA, Inc.
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and...
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 07h30 HE
|
Wave Life Sciences USA, Inc.
Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in...